Global Arthrogryposis Market, By Type (Distal Arthrogryposis Type 4 (scoliosis), Distal Arthrogryposis Type 2a, Distal Arthrogryposis Type 2b, Distal ArthrogryposisTtype 3, Distal Arthrogryposis Type 4, Distal Arthrogryposis Type 5, Distal Arthrogryposis Type 6, Distal Arthrogryposis Type 7, Distal Arthrogryposis Type 8, Distal Arthrogryposis Type 9, Distal Arthrogryposis Type 10), Treatment Type (Occupational Therapists, Physical Therapy, Surgery, Imaging Diagnostics, CT scan), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies and others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Global arthrogryposis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 3.70% in the above-mentioned research forecast period.
The arthrogryposis multiplex congenital (AMC) refers to numerous conditions involving the infant's limited joint movement. The infant’s activity is limited, since the mother’s uterus is oddly shaped or multiple sclerosis. More than 300 genetic disorders (such as spinal muscular atrophy type I and trisomy 18) have been associated with arthrogryposis multiplex congenital. The symptoms related to arthrogryposis are frozen joints, weakened muscles, and nerve impairment. If abnormal limbs are observed, the doctors may perform diagnostic imaging or ultrasounds of other parts of the fetus's body or genetic testing on the fetus using chorionic villus sampling or amniocentesis. Doctors may recommend parents seek genetic counseling. Muscle biopsy and electromyography can be done to help the doctors draw a comparison between various types of arthrogryposis. The rare disorder occurs in 1 out of every 3000 live births. The number of males and females affected by AMC is approximately equal. The condition has been reported in individuals of Asian, African, and European descent. Isolated congenital contractures affect about 1 in 500 individuals in the general population.
The increased incidence of arthrogryposis cases, rise in geriatric population, increasing number of government initiatives, ease of purchase, investment by R&D in pharmaceutical companies, increased demand for early diagnosis for arthrogryposis treatment are predicted to drive the market growth. However, the lack of health remuneration policies, rise in cost, side effects associated with the use of antibiotics is expected to hinder the market growth. The rise of emerging markets in developing countries, unmet medical needs, the increase of untapped opportunities, upcoming healthcare clinics are the opportunities that are projected to bolster the market growth. The lack of expertise, rise in the product (diagnostic machines) recalls, use of alternatives are the challenges that can hamper the market growth.
This arthrogryposis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Arthrogryposis Market Scope and Market Size
The arthrogryposis market is segmented on the basis of type, treatment type, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the arthrogryposis market is segmented into distal arthrogryposis type 4 (scoliosis), distal arthrogryposis type 2a, distal arthrogryposis type 2b, distal arthrogryposis type 3, distal arthrogryposis type 4, distal arthrogryposis type 5, distal arthrogryposis type 6, distal arthrogryposis type 7, distal arthrogryposis type 8, distal arthrogryposis type 9, distal arthrogryposis type 10.
- On the basis of treatment type, the arthrogryposis market is segmented into occupational therapists, physical therapy, surgery, imaging diagnostics, CT scan.
- On the basis of distribution channel, the arthrogryposis market has also been segmented into hospital pharmacies, retail pharmacies, direct tender and others.
Arthrogryposis Market Country Level Analysis
Arthrogryposis market is analysed and market size information is provided by country, type, treatment type, and distribution channel as referenced above.
The countries covered in the arthrogryposis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America is expected to hold the largest market share due to the rising number of mortality cases in infants, increased awareness among the population base Asia Pacific is also expected to account for the second largest market share due to the rise in point of care diagnostics, technological advancements for novel diagnostic machinery to detect and diagnose the genetic abnormalities, untapped opportunities in emerging markets.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Arthrogryposis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Arthrogryposis Market Share Analysis
Arthrogryposis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to arthrogryposis market.
The major players covered in the arthrogryposis market are Biochem Pharma, Zydus Cadila, GSK, Vernalis (R&D) Limited, Sanofi, Pfizer Inc, Galderma Laboratories, Mylan N.V., Johnson & Johnson Services, Inc, Medimetriks Pharmaceuticals, Inc, F-Hoffmann-La Roche, Illumina Inc, Thermo Fischer Scientific Inc, Takara Bio Inc, CENTOGENE N.V., Abbott among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.